PLANTATION, Fla., March 16, 2022 /PRNewswire/ - Akumin Inc.
(NASDAQ: AKU) (TSX: AKU) ("Akumin" or the "Company"), a national
partner of choice for U.S. hospitals, health systems and physician
groups, with comprehensive solutions addressing outsourced
radiology and oncology service line needs, announced today its
financial results for the quarter and year ended December 31, 2021.
Fourth Quarter 2021 Highlights
- Akumin delivered strong quarterly same store volume performance
on a consolidated, pro forma basis:
-
- +6.2% for MRI
- +4.2% for PET/CT
- +3.0% for Total Radiology Procedures
- +4.5% for Oncology Patient Starts
- The Company reported revenue totaling $179.4 million for the fourth quarter, a
$112.6 million or 168.3% increase
over the fourth quarter of last year. On a sequential basis,
revenue increased $71.3 million or
65.9% over the third quarter of 2021.
- Akumin generated $27.5 million of
Adjusted EBITDA (as defined below) for the quarter, a $14.0 million or 103.6% increase over the fourth
quarter of last year. On a sequential basis, Adjusted EBITDA
increased $9.6 million or 53.2% over
the third quarter of 2021.
Summary Consolidated Financial Results (in
thousands, except for per share amounts)
|
3-month period
ended
Dec 31, 2021
|
3-month period
ended
Dec 31, 2020
|
Year ended
Dec 31, 2021
|
Year ended
Dec 31, 2020
|
MRI Scans
|
217
|
86
|
539
|
326
|
PET-CT
Scans
|
32
|
2
|
46
|
6
|
Total
Scans
|
545
|
339
|
1,683
|
1,242
|
Oncology Patient
Starts
|
2
|
-
|
3
|
-
|
Revenue
|
$179,443
|
$66,879
|
$421,079
|
$245,626
|
Adjusted EBITDA
(1)
|
$27,522
|
$13,519
|
$66,903
|
$42,078
|
EPS
–Diluted
|
$(0.36)
|
$(0.27)
|
$(0.56)
|
$(0.52)
|
(1) See "Non-GAAP Measures"
below.
|
Commenting on the year-end results, Riadh Zine, Chairman and Co-Chief Executive
Officer of the Company, said, "Q4 2021 marked the first full
quarter of combined results following Akumin's acquisition of
Alliance HealthCare Services on September
1, 2021. We are pleased that we were able to deliver
financial results, well within our guidance range in the quarter,
notwithstanding the disruptions caused by Omicron and the impact of
an additional collection reserve related to the attorney business
because of court backlogs following a 15-month shutdown.
"Although Omicron continued to disrupt the business in the early
part of 2022, we are pleased that we have seen a strong rebound to
normalized levels which speaks to the resilience of Akumin's
business. As an essential healthcare service provider, we
continue to serve our valued patients and partners and we remain
optimistic that we will recover the pandemic-related volume lag in
the subsequent quarters, barring any unforeseen variants," Mr. Zine
continued.
"Akumin's vision is to drive patient-centered innovation,
service delivery standardization, and exceptional healthcare value,
all in an outpatient care setting to hospital and health system
relationships. Our integration and transformative initiatives
are underway, and we continue to expect 2022 to be a milestone year
as we build on this solid foundation" Mr. Zine concluded.
Unless otherwise indicated, all amounts are expressed in U.S.
dollars. Certain metrics, including those expressed on an
adjusted or comparable basis, are non-GAAP measures. See
"Non-GAAP Measures" and "Selected Consolidated Financial
Information" of this press release for further details.
As previously announced, effective January 1, 2022, the Company ceased to qualify as
a foreign private issuer in the United States. As a result,
from and after January 1, 2022, in
addition to other obligations, Akumin now files its annual
consolidated financial statements and management's discussions and
analysis on the Securities and Exchange Commission Form 10-K, the
U.S. domestic issuer form. Copies of these filings are
available in Akumin's public disclosure at www.sec.gov and
www.sedar.com.
Investor Presentation
Akumin would like to invite interested parties to an investor
presentation to be held on Thursday, March
17, 2022 from 8:00 a.m. to 9:00 a.m.
Eastern Time where management will discuss fourth quarter
and yearend results.
Conference call details:
Date:
|
8:00a.m. Eastern
Time, Thursday, March 17, 2022
|
Toll-free:
|
888-256-1007
|
International
Callers:
|
647-484-0478.
|
A related presentation will be available from Akumin's website
(www.akumin.com) and at https://akum.in/2021-ResultsCall.
Participants are asked to connect at least 10 minutes prior to the
beginning of the call to ensure participation. The webcast
archive will be available for 90 days. A replay of the
presentation will also be available by calling 1-888-203-1112, or
647-436-0148 for international callers, using passcode 4560419.
About Akumin
Akumin is a national partner of choice for U.S. hospitals,
health systems and physician groups, with comprehensive solutions
addressing outsourced radiology and oncology service line needs.
Akumin provides: (1) fixed-site outpatient diagnostic imaging
services through a network of more than 200 owned and/or operated
imaging locations; and (2) outpatient radiology and oncology
services and solutions to approximately 1,000 hospitals and health
systems across 46 states. By combining clinical and operational
expertise with the latest advances in technology and information
systems, Akumin facilitates more efficient and effective diagnosis
and treatment for patients and their providers. Akumin's
imaging procedures include MRI, CT, positron emission tomography
(PET and PET/CT), ultrasound, diagnostic radiology (X-ray),
mammography, and other interventional procedures; cancer care
services include a full suite of radiation therapy and related
offerings. For more information, visit www.akumin.com and
www.alliancehealthcareservices-us.com.
Non-GAAP Measures
This press release refers to certain non-GAAP measures. These
non-GAAP measures are not recognized measures under United States generally accepted accounting
principles ("GAAP") and do not have a standardized meaning
prescribed by GAAP. There is unlikely to be comparable or
similar measures presented by other companies. Rather, these
non-GAAP measures are provided as additional information to
complement those GAAP measures by providing further understanding
of our results of operations from management's perspective.
Accordingly, these non-GAAP measures should not be considered in
isolation nor as a substitute for analysis of our financial
information reported under GAAP. We use non-GAAP financial
measures, including "EBITDA", "Adjusted EBITDA" and "Adjusted
EBITDA Margin" (each as defined below). These non-GAAP measures are
used to provide investors with supplemental measures of our
operating performance and thus highlight trends in our core
business that may not otherwise be apparent when relying solely on
GAAP measures. We believe the use of these non-GAAP measures, along
with GAAP financial measures, enhances the reader's understanding
of our operating results and is useful to us and to investors in
comparing performance with competitors, estimating enterprise
value, and making investment decisions. We also believe that
securities analysts, investors, and other interested parties
frequently use non-GAAP measures in the evaluation of issuers. Our
management uses non-GAAP measures to facilitate operating
performance comparisons from period to period, to prepare annual
operating budgets and forecasts and to determine components of
management compensation. Definitions and reconciliations of
non-GAAP measures to the relevant reported measures can be found in
our Form 10-K filed March 16,
2022 available in our public disclosure at www.sec.gov and
www.sedar.com.
We define such non-GAAP measures as follows:
"EBITDA" means net income (loss) before interest expense
(net), income tax expense (benefit), and depreciation and
amortization.
"Adjusted EBITDA" means EBITDA, as further adjusted for
stock-based compensation, asset impairments, settlement and related
costs (recoveries), financial instrument revaluation and related
losses (gains), loss on extinguishment of debt, acquisition-related
costs, severance and related costs, restructuring charges, other
losses (gains), deferred rent expense (credit), and one-time
adjustments.
"Adjusted EBITDA Margin" means Adjusted EBITDA divided by the
total revenue in the period.
Forward-Looking Information
Certain information in this press release constitutes
forward-looking information or forward-looking statements. In
some cases, but not necessarily in all cases, such statements or
information can be identified by the use of forward-looking
terminology such as "plans", "targets", "expects" or "does not
expect", "is expected", "an opportunity exists", "is positioned",
"estimates", "intends", "assumes", "anticipates" or "does not
anticipate" or "believes", or variations of such words and phrases
or state that certain actions, events or results "may", "could",
"would", "might", "will" or "will be taken", "occur" or "be
achieved". In addition, any statements that refer to expectations,
projections or other characterizations of future events or
circumstances contain forward-looking information. Statements
containing forward-looking information are not historical facts but
instead represent management's expectations, estimates and
projections regarding future events.
Forward-looking information is necessarily based on a number of
opinions, assumptions and estimates that, while considered
reasonable by Akumin as of the date of this press release, are
subject to known and unknown risks, uncertainties, assumptions and
other factors that may cause the actual results, level of activity,
performance or achievements to be materially different from those
expressed or implied by such forward-looking information, including
but not limited to the factors described in greater detail in the
"Risk Factors" section of our Form 10-K filed March 16, 2022, which is available at www.sec.gov
and www.sedar.com. These factors are not intended to represent a
complete list of the factors that could affect Akumin; however,
these factors should be considered carefully. There can be no
assurance that such estimates and assumptions will prove to be
correct. The forward-looking statements contained in this
press release are made as of the date of this press release, and
Akumin expressly disclaims any obligation to update or alter
statements containing any forward-looking information, or the
factors or assumptions underlying them, whether as a result of new
information, future events or otherwise, except as required by
law.
Selected Consolidated Financial Information
(in
thousands)
|
Three-month
period
ended
Dec 31, 2021
|
Three-month
period
ended
Dec 31, 2020
|
$ Change
|
% Change
|
Service fees – net of
allowances and
discounts
|
177,202
|
62,283
|
114,919
|
185%
|
Other
revenue
|
2,241
|
4,596
|
(2,355)
|
(51%)
|
Revenue
|
179,443
|
66,879
|
112,564
|
168%
|
|
|
|
|
|
Employee
compensation
|
75,365
|
21,966
|
53,399
|
243%
|
Reading
fees
|
11,200
|
9,964
|
1,236
|
12%
|
Rent and
utilities
|
12,305
|
7,319
|
4,986
|
68%
|
Third party services
and professional
fees
|
31,233
|
7,269
|
23,964
|
330%
|
Administrative
|
10,616
|
3,351
|
7,265
|
217%
|
Medical supplies and
other expenses
|
14,610
|
3,178
|
11,432
|
360%
|
Depreciation and
amortization
|
24,536
|
4,059
|
20,477
|
504%
|
Stock-based
compensation
|
795
|
358
|
437
|
122%
|
Other operating
losses
|
305
|
352
|
(47)
|
(13%)
|
Interest
expense
|
28,354
|
8,344
|
20,010
|
240%
|
Settlement and related
recoveries
|
(145)
|
(167)
|
22
|
(13%)
|
Acquisition related
costs
|
5,821
|
605
|
5,216
|
nmf
|
Other non-operating
losses (gains)
|
(528)
|
18,198
|
(18,726)
|
(103%)
|
Loss before income
taxes
|
(35,024)
|
(17,917)
|
(17,107)
|
95%
|
Income tax expense
(benefit)
|
(8,392)
|
64
|
(8,456)
|
nmf
|
Non-controlling
interest
|
5,089
|
709
|
4,380
|
618%
|
Net loss
attributable to common
shareholders
|
(31,721)
|
(18,690)
|
(13,031)
|
70%
|
(in
thousands)
|
Year
Ended
Dec 31, 2021
|
Year
Ended
Dec 31, 2020
|
$ Change
|
% Change
|
Service fees – net of
allowances and
discounts
|
416,074
|
238,324
|
177,750
|
75%
|
Other
revenue
|
5,005
|
7,302
|
(2,297)
|
(31%)
|
Revenue
|
421,079
|
245,626
|
175,453
|
71%
|
|
|
|
|
|
Employee
compensation
|
164,053
|
84,038
|
80,015
|
95%
|
Reading
fees
|
42,842
|
37,818
|
5,024
|
13%
|
Rent and
utilities
|
37,158
|
30,203
|
6,955
|
23%
|
Third party services
and professional
fees
|
63,301
|
30,183
|
33,118
|
110%
|
Administrative
|
24,660
|
12,231
|
12,429
|
102%
|
Medical supplies and
other expenses
|
27,721
|
11,162
|
16,559
|
148%
|
Depreciation and
amortization
|
44,895
|
17,060
|
27,835
|
163%
|
Stock-based
compensation
|
2,792
|
2,084
|
708
|
34%
|
Other operating losses
(gains)
|
583
|
(4,130)
|
4,713
|
(114%)
|
Interest
expense
|
62,575
|
32,781
|
29,794
|
91%
|
Settlement and related
costs
(recoveries)
|
(539)
|
2,324
|
(2,863)
|
(123%)
|
Acquisition related
costs
|
20,233
|
1,079
|
19,154
|
nmf
|
Other non-operating
losses (gains)
|
(3,990)
|
22,387
|
(26,377)
|
(118%)
|
Loss before income
taxes
|
(65,205)
|
(33,594)
|
(31,611)
|
94%
|
Income tax expense
(benefit)
|
(30,391)
|
562
|
(30,953)
|
nmf
|
Non-controlling
interest
|
8,477
|
2,585
|
5,892
|
228%
|
Net loss
attributable to common
shareholders
|
(43,291)
|
(36,741)
|
(6,550)
|
(18%)
|
(in
thousands)
|
Three-month
period
ended
Dec 31, 2021
|
Three-month
period
ended
Dec 31, 2020
|
Year
ended
Dec 31, 2021
|
Year
ended
Dec 31, 2020
|
Net
loss
|
(26,632)
|
(17,981)
|
(34,814)
|
(34,156)
|
Income tax expense
(benefit)
|
(8,392)
|
64
|
(30,391)
|
562
|
Depreciation and
amortization
|
24,536
|
4,059
|
44,895
|
17,060
|
Interest
expense
|
28,354
|
8,344
|
62,575
|
32,781
|
EBITDA
|
17,866
|
(5,514)
|
42,265
|
16,247
|
Adjustments:
|
|
|
|
|
Stock-based
compensation
|
795
|
358
|
2,792
|
2,084
|
Settlement and related
costs
(recoveries)
|
(145)
|
(167)
|
(539)
|
2,324
|
Acquisition-related
costs
|
5,821
|
605
|
20,233
|
1,079
|
Gain on revaluation of
earn-out
liability
|
-
|
-
|
-
|
(5,457)
|
Loss on extinguishment
of debt
|
-
|
18,279
|
-
|
18,279
|
Loss (gain) on
settlement of
interest rate cap derivative
|
-
|
(101)
|
-
|
4,162
|
Gain on conversion of
debt to
equity investment
|
-
|
-
|
(3,360)
|
-
|
Other losses,
net
|
72
|
108
|
342
|
407
|
Severance,
restructuring and other
charges
|
2,836
|
-
|
3,368
|
-
|
Deferred rent
expense(1)
|
277
|
(49)
|
1,802
|
2,953
|
Adjusted
EBITDA
|
27,522
|
13,519
|
66,903
|
42,078
|
Revenue
|
179,443
|
66,879
|
421,079
|
245,626
|
Adjusted EBITDA
Margin
|
15%
|
20%
|
16%
|
17%
|
|
(1) Deferred
rent expense is defined as operating lease cost less operating cash
flows from operating leases and adjusted for any prepayments or
related items.
|
View original
content:https://www.prnewswire.com/news-releases/akumin-announces-fourth-quarter-2021-results-301504494.html
SOURCE Akumin Inc.